Decrease in Anogenital Distance among Male Infants with Prenatal Phthalate Exposure

Shanna H. Swan,1 Katharina M. Main,2 Fan Liu,3 Sara L. Stewart,3 Robin L. Kruse,3 Antonia M. Calafat,4 Catherine S. Mao,5 J. Bruce Redmon,6 Christine L. Ternand,7 Shannon Sullivan,8 J. Lynn Teague,9 and the Study for Future Families Research Team*

1Department of Obstetrics and Gynecology, University of Rochester, Rochester, New York, USA; 2Department of Growth and Reproduction, University of Copenhagen, Copenhagen, Denmark; 3Department of Family and Community Medicine, University of Missouri-Columbia, Columbia, Missouri, USA; 4National Center for Environmental Health, Centers for Disease Control and Prevention, Division of Laboratory Sciences, Atlanta, Georgia, USA; 5Department of Pediatrics, Division of Endocrinology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, California, USA; Departments of 6Pediatrics and 7Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA; 8Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA; 9Departments of Surgery (Urology) and Child Health, University of Missouri-Columbia, Columbia, Missouri, USA

As with the Colón et al. study, contamination from diesters in laboratory equipment could not be excluded (Murature et al. 1987).

More recent studies have examined phthalate monoester metabolites in urine. Because urinary metabolites are not likely to be present as the result of contamination, these studies avoid this potential source of measurement error. Duty et al. (2003a) reported dose–response relationships between tertiles of monobutyl phthalate and sperm motility and sperm concentration, and between tertiles of monobenzyl phthalate (MBzP) and sperm concentration. They also reported inverse dose–response relationships between monoethyl phthalate (MEP) and sperm DNA damage.

Prenatal phthalate exposure impairs testicular function and shortens anogenital distance (AGD) in male rodents. We present data from the first study to examine AGD and other genital measurements in relation to prenatal phthalate exposure in humans. A standardized measure of AGD was obtained in 134 boys 2–36 months of age. AGD was significantly correlated with penile volume (R = 0.27, p = 0.001) and the proportion of boys with incomplete testicular descent (R = 0.20, p = 0.02). We defined the anogenital index (AGI) as AGD divided by weight at examination [AGI = AGD/weight (mm/kg)] and calculated the age-adjusted AGI by regression analysis. We examined nine phthalate monoester metabolites, measured in prenatal urine samples, as predictors of age-adjusted AGI in regression and categorical analyses that included all participants with prenatal urine samples (n = 85). Urinary concentrations of four phthalate metabolites [monoethyl phthalate (MEP), mono-n-butyl phthalate (MBP), monobenzyl phthalate (MBzP), and monoisobutyl phthalate (MiBP)] were inversely related to AGI. After adjusting for age at examination, p-values for regression coefficients ranged from 0.007 to 0.097. Comparing boys with prenatal MBP concentration in the highest quartile with those in the lowest quartile, the odds ratio for a shorter than expected AGI was 10.2 (95% confidence interval, 2.5 to 42.2). The corresponding odds ratios for MEP, MBzP, and MiBP were 4.7, 3.8, and 9.1, respectively (all p-values < 0.05). We defined a summary phthalate score to quantify joint exposure to these four phthalate metabolites. The age-adjusted AGI decreased significantly with increasing phthalate score (p-value for slope = 0.009).

Diesters of phthalic acid, commonly referred to as phthalates, are widely used in industry and commerce; they are used in personal care products (e.g., makeup, shampoo, and soaps), plastics, paints, and some pesticide formulations. Consistent toxicologic evidence indicates association between several of these phthalate esters and reproductive effects. In particular, dibutyl phthalate (DBP), benzylbutyl phthalate (BzBP), di-2-ethylhexyl phthalate (DEHP), and di-isononyl phthalate (DiNP) have been shown to disrupt reproductive tract development in male rodents in an antian- drogenic manner (Parks et al. 2000). Recent studies have reported significant reductions in anogenital distance (AGD) in Sprague-Dawley rats after prenatal exposure at high doses to BzBP (Nagao et al. 2000; Tyl et al. 2004), DBP (Barlow and Foster 2003; Foster et al. 2000), and DEHP (Gray et al. 2000; Parks et al. 2000).

Despite the growing body of literature on phthalate reproductive toxicity and data demonstrating extensive human exposure (Silva et al. 2004a), few studies have examined the effects of these chemicals on human reproductive development. Colón et al. (2000) reported elevated levels of several phthalates [including diethyl phthalate (DEP), DBP, and DEHP] in serum samples from young girls with premature breast development. However, the timing of exposure was unknown and high exposure levels may have reflected phthalate contamination of serum samples (McKee and Toxicology Research Task Group 2004). Until recently, the only study of humans to evaluate phthalate exposure and male reproductive toxicity measured phthalate diesters in semen.

Address correspondence to S.H. Swan, University of Rochester, Department of Obstetrics and Gynecology, School of Medicine and Dentistry, 601 Elmwood Ave., Box 668, Rochester, NY 14642-8668 USA. Telephone: (585) 273-3521. Fax: (585) 275-7366. E-mail: shanna_swan@urmc.rochester.edu

*The Study for Future Families Research Team included, from the University of Missouri-Columbia: E.Z. Drobnis, B.S. Carter, D. Kelly, and J. Reidy; the University of Minnesota: C. Kwong and A. Muehlen. The members at University Physicians Clinic (Columbia, MO), Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (Los Angeles, CA), and University of Iowa: A. Sparks, A. Wolf, J. Whitham, M. Hattersman-Zogg, and M. Maifeld.

We thank the health care providers and study participants at University Physicians Clinic (Columbia, MO), Fairview Riverside Women’s Clinic (Minne- apolis, MN), Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (Los Angeles, CA), Cedars-Sinai Medical Center (Los Angeles, CA), and University of Iowa Hospitals and Clinics (Iowa City, IA). We also thank M. Silva, J. Reidy, E. Samandar, and J. Preau for phthalate analyses and E. Gray, P. Foster, and D. Barr for their guidance.

This work was supported by grants from the U.S. Environmental Protection Agency and the National Institutes of Health (R01-ES09916 to the University of Missouri, MO1-RR04040 to the University of Minnesota, MO1-RR0425 to Harbor-UCLA Medical Center) and by grant 18018278 from the University of Minnesota Medical School (Columbia, MO).
measured using the neutral single-cell gel electrophoresis (comet) assay (Duty et al. 2003b). In this population of men attending an infertility clinic, increased urinary concentration of MBzP was also associated with decreased follicle stimulating hormone, whereas increases in monobutyl phthalate were marginally associated with increased inhibin-B (Duty et al. 2005).

Newborn male rodents have no scrotum, and the external genitalia are undeveloped; only a genital tubercle is apparent for both sexes. The distance from the anus to the insertion of this tubercle, the AGD, is androgen dependent and about twice as long in males as in females. The AGD has been shown to be a sensitive measure of prenatal antiandrogen exposure (Rhees et al. 1997). Recently, Salazar-Martinez et al. (2004) studied AGD in 45 male and 42 female infants. They measured the distance from the anus to the base of the scrotum in males and from the anus to the base of the genitals (the fourchette) in females. By these measures, AGD was sexually dimorphic and about twice as long in males as in females. No other studies have examined AGD among human males, although two other studies have evaluated AGD in female infants (Callegari et al. 1987; Phillip et al. 1996).

**Materials and Methods**

**Study participants.** Women included in our study were originally recruited into the first phase of the Study for Future Families (SFFI), a multicenter pregnancy cohort study, at prenatal clinics in Los Angeles, California (Harbor-UCLA and Cedars-Sinai), Minneapolis, Minnesota (University of Minnesota Health Center), and Columbia, Missouri (University Physicians), from September 1999 through August 2002. Data collection is still ongoing in Iowa, where a center was added late in SFFI, so Iowa participants are not included in this analysis. Methods are described in detail elsewhere (Swan et al. 2003). Briefly, couples whose pregnancy was not medically assisted were eligible unless the woman or her partner was < 18 years of age, either partner did not read and speak Spanish or English, or the father was unavailable or unknown. All participants completed a questionnaire, most gave blood samples, and after urine collection was added midway through the study, most also gave a urine sample.

Eighty-five percent of SFFI participants agreed to be recontacted, and we invited these mothers to take part in our follow-up study. The family was eligible for the follow-up study (SFFII) if the pregnancy ended in a live birth, the baby was 2–36 months of age, and the mother lived within 50 mi of the clinic and could attend at least one study visit. Here we report on results from the first study visit only. Human subject committees at all participating institutions approved SFFI and SFFII, and all participants signed informed consents for each study.

**Physical examination.** After standard anthropometric measurements (height, weight, head circumference, and skin-fold thickness) were obtained, a detailed examination of the breasts and genitals was conducted under the supervision of pediatric physicians who were trained in its administration. Every attempt was made to standardize the examination, which was developed specifically for this study. These methods included training sessions before and during the study and the use of standardized equipment. Neither the pediatric physicians nor the support staff had any knowledge of the mother’s phthalate concentrations.

Boys’ genital examinations included a description of the testes and scrotum, location and size of each testicle, and measurement of the penis. The placement of each testicle was initially coded in six categories; in the present analysis, boys are dichotomized into those with normal testicular descent (placement of both testes coded as normal or normal retracted) or with incomplete testicular descent (all other cases). The scrotum was categorized as distinct from surrounding tissue or not, and by size (small or not). Penile width and (stretched) length were recorded, and penile volume (proportional to (penile width/2)² × penile length) was calculated. We recorded the AGD, measured from the center of the anus to the anterior base of the penis. We also recorded the anogenital distance (ASD), measured from the center of the anus to the posterior base of the scrotum. This latter measurement was used by Salazar-Martinez et al. (2004), who refer to it as AGD.

**Phthalate metabolite analysis.** Urinary phthalate metabolite analyses were carried out by the Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC), which had no access to participant data. The analytical approach for the analysis of urinary phthalate metabolites (Silva et al. 2004b) is a modification of previously published methods (Silva et al. 2003). The analysis involves the enzymatic deconjugation of the phthalate metabolites from their glucuronidated form, automated on-line solid-phase extraction, separation with high-performance liquid chromatography, and detection by isotope-dilution tandem mass spectrometry. This high-throughput method allows for the simultaneous quantification in human urine of the nine phthalate metabolites reported in this study. Limits of detection (LOD) are in the low nanogram per milliliter range. Isotopically labeled internal standards were used along with conjugated internal standards to increase precision and accuracy of the measurements. The method is accurate (spiked recoveries are near 100%), and precise with between-day relative standard deviations of < 10%. Quality control (QC) samples and laboratory blanks were analyzed along with unknown samples to monitor performance of the method. The metabolite concentrations reported here are from 85 prenatal maternal urine samples of a total of 214 that also included postnatal maternal and baby samples from the same mothers and their children. The 214 samples were analyzed for phthalate metabolites in six batches, none of which had to be re-extracted for QC failures. Of the 214 samples, seven were re-extracted using < 1 mL of urine because concentrations of MEP calculated using 1 mL were above the linear range of the method.

**Statistical analysis.** After examining descriptive and summary statistics for all study variables, we explored models for AGD. We fit several alternative measures of body size (weight, height, and body mass index) and both additive and multiplicative functions of these. We defined the anogenital index (AGI = AGD/weight (mm/kg)) as a weight-normalized index of AGD.

AGD and AGI were modeled as both linear and quadratic functions of age. For babies born at < 38 weeks, age at examination in the first year was calculated from the estimated date of conception instead of the birth date. Once the best fitting model was identified, we plotted the expected AGI and its 25th and 75th percentiles as a function of age. We categorized boys in two ways: We dichotomized boys into those with AGI smaller than or at least as large as expected, and we used the difference between observed and expected AGI to define three groups of boys, short (AGI < 25th percentile for age), intermediate (25th percentile ≤ AGI < 75th percentile), and long (AGI ≥ 75th percentile for age) AGI. We also calculated the proportion of boys in these three groups with normal testicular descent (both testes normal or normal retracted) and normal scrotal (scrotum of normal size and distinct from surrounding tissue). We used the correlation between AGD and AGI and penile volume, testicular placement and scrotal parameters (size and distinctness from surrounding tissue). Our decision to use AGI as the measure of genital development was made, and cut points for categorical analyses of outcomes were selected, before obtaining phthalate metabolite values.

We used general linear models to explore the relationships between phthalate metabolite concentration (unadjusted for urine concentration) and genital parameters. Most metabolite concentrations were above the LOD; those below the LOD were assigned the value LOD divided by the square root of 2, which has been recommended when the data are not highly skewed, as was the case here (Hornung and...
have genitourinary malformations or disease were detected, and no parameters appeared grossly abnormal. The mean age at first examination was 15.9 months, and mean weight was 10.5 kg (Table 2). Mean (± SD) AGD was 70.3 ± 11.0 mm, with a distribution that was well approximated by a normal curve. Overall, 86.6% of boys had both tests classified as normal or normal-retractile.

A prenatal urine sample was assayed for phthalate metabolites for mothers of 85 of these boys. These mother–son pairs comprise the study sample included in this analysis. We refer to these as AGI-associated phthalates. Because phthalate metabolite concentrations are highly correlated, and because our limited sample size precluded us from examining multiway interactions, we constructed a summary phthalate score to examine the effect of joint exposure to more than one AGI-associated phthalate. For this purpose, we used quartiles of metabolite concentration; values in the lowest quartile did not contribute to the summary score, whereas higher values increased the score one unit per quartile. We divided this sum into three categories: low (0–1, reflecting little or no exposure to AGI-associated phthalates), intermediate (2–10), and high (11–12, reflecting high exposure to all, or almost all, AGI-associated phthalates). We examined the magnitude of the residual (observed – expected) AGI as a function of this summary phthalate score.

Results

The population for the present analysis was identified from families recruited in California, Minnesota, or Missouri for whom data entry was complete by 17 December 2004, the cutoff date for the present analysis. At that time, 654 participants from these three centers had completed SFFII and given permission to be recontacted. Of these, 477 (72.9%) were eligible for SFFII and 346 (72.5%) participated (Table 1). SFFII participants were demographically similar to nonparticipants except that nonparticipants were more likely to be Hispanic. Of the 172 boys born to these mothers, we excluded 5 boys in twin births, 10 boys with incomplete data, and 23 boys for whom AGD was not recorded (two whose mothers declined the genital exam, with the remainder older boys [mean age, 19.6 months], for whom the study examiner felt the measurement was not reliable, usually because of the boys’ activity level). The remaining 134 boys comprise the sample used for the analysis of AGD and other genital measurements. Among the 134 boys for whom we have genitourinary malformations or disease were detected, and no parameters appeared grossly abnormal. The mean age at first examination was 15.9 months, and mean weight was 10.5 kg (Table 2). Mean (± SD) AGD was 70.3 ± 11.0 mm, with a distribution that was well approximated by a normal curve. Overall, 86.6% of boys had both tests classified as normal or normal-retractile.

A prenatal urine sample was assayed for phthalate metabolites for mothers of 85 of these boys. These mother–son pairs comprise the study sample included in this analysis. We refer to these as AGI-associated phthalates. Because phthalate metabolite concentrations are highly correlated, and because our limited sample size precluded us from examining multiway interactions, we constructed a summary phthalate score to examine the effect of joint exposure to more than one AGI-associated phthalate. For this purpose, we used quartiles of metabolite concentration; values in the lowest quartile did not contribute to the summary score, whereas higher values increased the score one unit per quartile. We divided this sum into three categories: low (0–1, reflecting little or no exposure to AGI-associated phthalates), intermediate (2–10), and high (11–12, reflecting high exposure to all, or almost all, AGI-associated phthalates). We examined the magnitude of the residual (observed – expected) AGI as a function of this summary phthalate score.

Results

The population for the present analysis was identified from families recruited in California, Minnesota, or Missouri for whom data entry was complete by 17 December 2004, the cutoff date for the present analysis. At that time, 654 participants from these three centers had completed SFFII and given permission to be recontacted. Of these, 477 (72.9%) were eligible for SFFII and 346 (72.5%) participated (Table 1). SFFII participants were demographically similar to nonparticipants except that nonparticipants were more likely to be Hispanic. Of the 172 boys born to these mothers, we excluded 5 boys in twin births, 10 boys with incomplete data, and 23 boys for whom AGD was not recorded (two whose mothers declined the genital exam, with the remainder older boys [mean age, 19.6 months], for whom the study examiner felt the measurement was not reliable, usually because of the boys’ activity level). The remaining 134 boys comprise the sample used for the analysis of AGD and other genital measurements. Among the 134 boys for whom we have genitourinary malformations or disease were detected, and no parameters appeared grossly abnormal. The mean age at first examination was 15.9 months, and mean weight was 10.5 kg (Table 2). Mean (± SD) AGD was 70.3 ± 11.0 mm, with a distribution that was well approximated by a normal curve. Overall, 86.6% of boys had both tests classified as normal or normal-retractile.

A prenatal urine sample was assayed for phthalate metabolites for mothers of 85 of these boys. These mother–son pairs comprise the study sample included in this analysis. We refer to these as AGI-associated phthalates. Because phthalate metabolite concentrations are highly correlated, and because our limited sample size precluded us from examining multiway interactions, we constructed a summary phthalate score to examine the effect of joint exposure to more than one AGI-associated phthalate. For this purpose, we used quartiles of metabolite concentration; values in the lowest quartile did not contribute to the summary score, whereas higher values increased the score one unit per quartile. We divided this sum into three categories: low (0–1, reflecting little or no exposure to AGI-associated phthalates), intermediate (2–10), and high (11–12, reflecting high exposure to all, or almost all, AGI-associated phthalates). We examined the magnitude of the residual (observed – expected) AGI as a function of this summary phthalate score.

Results

The population for the present analysis was identified from families recruited in California, Minnesota, or Missouri for whom data entry was complete by 17 December 2004, the cutoff date for the present analysis. At that time, 654 participants from these three centers had completed SFFII and given permission to be recontacted. Of these, 477 (72.9%) were eligible for SFFII and 346 (72.5%) participated (Table 1). SFFII participants were demographically similar to nonparticipants except that nonparticipants were more likely to be Hispanic. Of the 172 boys born to these mothers, we excluded 5 boys in twin births, 10 boys with incomplete data, and 23 boys for whom AGD was not recorded (two whose mothers declined the genital exam, with the remainder older boys [mean age, 19.6 months], for whom the study examiner felt the measurement was not reliable, usually because of the boys’ activity level). The remaining 134 boys comprise the sample used for the analysis of AGD and other genital measurements. Among the 134 boys for whom we have genitourinary malformations or disease were detected, and no parameters appeared grossly abnormal. The mean age at first examination was 15.9 months, and mean weight was 10.5 kg (Table 2). Mean (± SD) AGD was 70.3 ± 11.0 mm, with a distribution that was well approximated by a normal curve. Overall, 86.6% of boys had both tests classified as normal or normal-retractile.

A prenatal urine sample was assayed for phthalate metabolites for mothers of 85 of these boys. These mother–son pairs comprise the study sample included in this analysis. We refer to these as AGI-associated phthalates. Because phthalate metabolite concentrations are highly correlated, and because our limited sample size precluded us from examining multiway interactions, we constructed a summary phthalate score to examine the effect of joint exposure to more than one AGI-associated phthalate. For this purpose, we used quartiles of metabolite concentration; values in the lowest quartile did not contribute to the summary score, whereas higher values increased the score one unit per quartile. We divided this sum into three categories: low (0–1, reflecting little or no exposure to AGI-associated phthalates), intermediate (2–10), and high (11–12, reflecting high exposure to all, or almost all, AGI-associated phthalates). We examined the magnitude of the residual (observed – expected) AGI as a function of this summary phthalate score.

Results

The population for the present analysis was identified from families recruited in California, Minnesota, or Missouri for whom data entry was complete by 17 December 2004, the cutoff date for the present analysis. At that time, 654 participants from these three centers had completed SFFII and given permission to be recontacted. Of these, 477 (72.9%) were eligible for SFFII and 346 (72.5%) participated (Table 1). SFFII participants were demographically similar to nonparticipants except that nonparticipants were more likely to be Hispanic. Of the 172 boys born to these mothers, we excluded 5 boys in twin births, 10 boys with incomplete data, and 23 boys for whom AGD was not recorded (two whose mothers declined the genital exam, with the remainder older boys [mean age, 19.6 months], for whom the study examiner felt the measurement was not reliable, usually because of the boys’ activity level). The remaining 134 boys comprise the sample used for the analysis of AGD and other genital measurements. Among the 134 boys for whom we...
coefficients for the oxidative monoester metabolites of DEHP, mono-2-ethyl-5-oxo-hexyl phthalate (MEOH), and mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP) were of a magnitude comparable with those for MEP, MBzP, and MiBP. The model predicting ASD as a function of baby’s age and weight fit poorly (adjusted $R^2 = 0.10$). The fit for the model using ASD/weight as a function of age and age squared was better (adjusted $R^2 = 0.47$) but did not fit as well as the model using AGI ($R^2 = 0.61$). ASD/weight was associated with MEP concentration (regression coefficient = $-0.429$; 95% CI, $-0.722$ to $-0.137$). For the other phthalate metabolites, regression coefficients were less significant (all $p$-values between 0.11 and 0.97).

**Summary phthalate score.** We used the summary phthalate score as defined in “Materials and Methods” to study the effect of joint exposure to more than one AGI-associated phthalate. The summary phthalate score was directly related to the proportion of boys with short AGI ($p = 0.001$). Of the 10 boys whose phthalate scores were high (score = 11–12), all but one had a short AGI. Conversely, of the 11 boys whose scores were low (score = 0 or 1), only one had a short AGI. The ORs for having a short AGI for high summary phthalate score compared with low (OR = 90.0; 95% CI, 4.88 to 1,659), and high compared with medium (29.4; 95% CI, 3.4 to 251) were large and significant, although the confidence intervals were very wide. These data are shown graphically in Figure 1.

**Discussion**

In the recent National Health and Nutrition Examination Survey (NHANES 1999–2000), most of the general population in the United States had measurable exposure to multiple phthalates (CDC 2003; Silva et al. 2004a). The samples in the present study and in NHANES were both analyzed using comparable methods and standards by the same laboratory, although the specific metabolites that were measured in the two studies differed somewhat. We compared the medians and 75th percentiles of the AGI-associated phthalate metabolite concentrations among two groups of mothers in our study (those whose boys fell in the short AGI group and all others) with those of females in the NHANES sample (Table 7). In the analysis of the NHANES samples, monobutyl phthalate includes both MBP and MiBP, which were measured separately in our study. Metabolite concentrations for mothers of boys with short AGI were consistently higher than those of other mothers. Compared with women in the NHANES sample, metabolite concentrations for our population were somewhat lower. However, our population cannot be directly compared with

![Graph](image-url)
NHNES: the proportion of pregnant women in the NHANES sample is unknown, and age distributions differ. Nonetheless, these data demonstrate that the four AGI-associated phthalate metabolites are prevalent in the U.S. female population, and levels were not unusually high among mothers whose sons had a short AGI.

Although not identical, AGD in pups is most similar to AGD as we defined it in this study. In rodents, AGD has been shown to be one of the most sensitive end points for phthalates such as DBP (Mylchreest et al. 2000) and other antiandrogens such as flutamide (Barlow and Foster 2003; McIntyre et al. 2001) and finasteride (Bowman et al. 2003). It is difficult to compare the dose to humans from low-level, ongoing, environmental exposure with that delivered to rodents experimentally in a narrow window of gestation. Nonetheless, it is likely that the doses to which our participants were exposed are lower than those used in toxicologic settings, suggesting that humans may be more sensitive to prenatal phthalate exposure than rodents. This greater sensitivity in humans has been observed for other toxicants. For example, humans are more sensitive than rodents to trenbolone by an order of magnitude (Neumann 1976). This greater sensitivity is thought to be a result of rodents’ higher metabolic rate and more rapid inactivation of toxicants, both of which have been shown to be inversely related to body size (White and Seymour 2005).

In light of the toxicologic literature for MBP, MBzP, and MiBP (Ema et al. 2003; Foster et al. 1980, 1981; Gray et al. 2000; Nakahara et al. 2003), our data suggest that the end points affected by these phthalates are quite consistent across species. A boy with short AGI has, on average, an AGI that is 18% shorter than expected based on his age and weight as well as an increased likelihood of testicular maldescent, small and indistinct scrotum, and smaller penile size. These changes in AGD and testicular descent are consistent with those reported in rodent studies after high-dose phthalate exposure (Ema et al. 2003; Gray et al. 2000; Mylchreest et al. 2000). The lack of association for MCPP and MMP, which have not been widely studied, is not inconsistent with the toxicologic literature.

With respect to DEP and its metabolite MEP, we note that there are three other human studies suggesting reproductive toxicity (Colón et al. 2000; Duty et al. 2003b; Main KM, unpublished data). It is therefore uncertain whether the absence of data in rodents showing reproductive toxicity is the result of failure to detect it, unmeasured confounding in human studies, or interspecies differences in response to these compounds.

DEHP has been shown to shorten AGD (Gray et al. 2000) and reduce testosterone (Parks et al. 2000). Although MEHP was not associated with AGD in our data, the associations for the oxidative metabolites of DEHP (MEOHP and MEHHP) were of comparable magnitude with those for metabolites of DBP and BzBP, although not statistically significant. Thus, it is unclear whether MEOHP and MEHHP are (inversely) associated with AGI, although associations are of borderline statistical significance because of our sample size, or whether human and rodent responses to this phthalate and its metabolites differ.

Masculinization of external male genitalia, represented by longer AGD, is controlled by dihydrotestosterone (Clark et al. 1990). Ema and Miyawaki (2001) demonstrated that this metabolite of testosterone is markedly decreased by prenatal administration of MBP, suggesting that MBP acts as an antiandrogen. AGD in male rodents is associated with other adverse developmental effects (Foster and McIntyre 2002) and some phthalate-induced changes have been shown to be permanent. For example, Barlow et al. (2004) report that prenatal exposure to 500 mg/kg/day DBP resulted in permanently decreased AGD and testicular dysgenesis. They also report that in utero DBP exposure induced proliferative Leydig cell lesions. Follow-up of exposed children until adulthood will be required to determine whether long-term effects, including testicular dysgenesis, are seen in humans after prenatal phthalate exposure.

Several recent studies of the variability of phthalate monooester concentration in human samples suggest that phthalate concentration in humans is fairly stable, perhaps reflecting habitual use of phthalate-containing household and consumer products (Colón et al. 2000; Hauser et al. 2004; Hoppin et al. 2002). These studies lend support to the use of a single sample for exposure assessment. We obtained only a single prenatal urine sample from each woman, and most samples were obtained quite late in pregnancy (mean = 28.3 weeks). Therefore, the measured phthalate metabolite levels may not reflect exposure during the most sensitive developmental window, resulting in some degree of exposure misclassification. However, unless this misclassification varied systematically with outcome, such errors would bias the effect estimate toward the null. In fact, the categorical analysis, which should be less sensitive to such misclassification, showed

### Table 5. Mean (median) phthalate monooester metabolite levels by AGI category.

<table>
<thead>
<tr>
<th>Monooester metabolite</th>
<th>AGI category [mean (median; ng/mL)]</th>
<th>Long (n = 17)</th>
<th>Intermediate (n = 43)</th>
<th>Short (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEP</td>
<td>AGI &lt; expected</td>
<td>12.1 (11.5)</td>
<td>22.2 (13.1)</td>
<td>38.7 (24.5)</td>
</tr>
<tr>
<td>MBzP</td>
<td>AGI ≥ 75th percentile of expected AGI</td>
<td>10.6 (6.6)</td>
<td>15.1 (7.7)</td>
<td>25.8 (16.1)</td>
</tr>
<tr>
<td>MBP</td>
<td>AGI &lt; 75th percentile of expected AGI</td>
<td>13.1 (11.5)</td>
<td>24.5 (12.1)</td>
<td>38.7 (24.5)</td>
</tr>
<tr>
<td>MiBP</td>
<td>AGI ≥ 75th percentile of expected AGI</td>
<td>124 (47.1)</td>
<td>592 (112)</td>
<td>1,076 (225)</td>
</tr>
<tr>
<td>MEP</td>
<td>AGI &lt; 75th percentile of expected AGI</td>
<td>2.3 (1.5)</td>
<td>3.3 (2.1)</td>
<td>7.7 (4.8)</td>
</tr>
</tbody>
</table>

*Long, AGI ≥ 75th percentile of expected AGI. Intermediate, 25th percentile ≤ AGI < 75th percentile of expected AGI.

### Table 6. OR (95% CI) for AGI less than expected from regression model, by monooester metabolite level.

<table>
<thead>
<tr>
<th>Monooester metabolite</th>
<th>Level (percentile)</th>
<th>AGI &lt; expected</th>
<th>AGI ≥ expected</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBP</td>
<td>Low</td>
<td>5</td>
<td>15</td>
<td>Reference</td>
</tr>
<tr>
<td></td>
<td>Medium</td>
<td>24</td>
<td>19</td>
<td>3.8 (1.2 to 12.3)</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>17</td>
<td>5</td>
<td>10.2 (2.5 to 42.2)</td>
</tr>
<tr>
<td>MBzP</td>
<td>Low</td>
<td>6</td>
<td>13</td>
<td>Reference</td>
</tr>
<tr>
<td></td>
<td>Medium</td>
<td>26</td>
<td>18</td>
<td>3.1 (1.002 to 9.8)</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>14</td>
<td>8</td>
<td>3.8 (1.03 to 13.9)</td>
</tr>
<tr>
<td>MEP</td>
<td>Low</td>
<td>7</td>
<td>14</td>
<td>Reference</td>
</tr>
<tr>
<td></td>
<td>Medium</td>
<td>25</td>
<td>19</td>
<td>2.6 (0.9 to 7.8)</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>14</td>
<td>6</td>
<td>4.7 (1.2 to 17.4)</td>
</tr>
<tr>
<td>MBP</td>
<td>Low</td>
<td>6</td>
<td>16</td>
<td>Reference</td>
</tr>
<tr>
<td></td>
<td>Medium</td>
<td>23</td>
<td>18</td>
<td>3.4 (1.1 to 10.5)</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>17</td>
<td>5</td>
<td>9.1 (2.3 to 35.7)</td>
</tr>
</tbody>
</table>

Low, < 25th percentile; medium, ≥ 25th and < 75th percentile; high, ≥ 75th percentile.

### Table 7. Concentrations of four phthalate metabolites in three groups of women (ng/mL).

| Monooester metabolite | Percentile | This study | NHANES *  
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Short AGI</td>
<td>Others</td>
</tr>
<tr>
<td>MEP</td>
<td>50th</td>
<td>24.5</td>
<td>12.1</td>
</tr>
<tr>
<td></td>
<td>75th</td>
<td>44.8</td>
<td>20.0</td>
</tr>
<tr>
<td>MiBP</td>
<td>50th</td>
<td>16.1</td>
<td>7.2</td>
</tr>
<tr>
<td></td>
<td>75th</td>
<td>27.5</td>
<td>17.8</td>
</tr>
<tr>
<td>MBP</td>
<td>50th</td>
<td>225</td>
<td>90.4</td>
</tr>
<tr>
<td></td>
<td>75th</td>
<td>551</td>
<td>281</td>
</tr>
<tr>
<td>MEP</td>
<td>50th</td>
<td>4.8</td>
<td>2.1</td>
</tr>
<tr>
<td></td>
<td>75th</td>
<td>12.1</td>
<td>4.3</td>
</tr>
</tbody>
</table>

* Females only (CDC 2003). *MiBP in the NHANES analysis includes both MBP and MiBP; in this study these metabolites were measured separately.
Prenatal phthalate exposure and male anogenital distance

stronger associations than did the continuous analysis.

Our analysis is based on a single measure of AGD, and the reliability of this measurement in humans has not been established. During two training sessions, three study physicians each measured AGD in four male infants (mean age, 8.1 months). The mean AGD for these measurements was 58.6 ± 5.2 mm, which is consistent with this proposed link to male reproductive development during the human testicular dysgenesis syndrome. Reproduction 127:305–315.


Barlow NJ, McIntyre BS, Foster PM. 2004. Male reproductive tract lesions at 6, 12, and 18 months of age following in utero exposure to di-(n-butyl) phthalate. Toxicol Pathol 32:78–95.


Skakkebaek NE, Rajpert-De Meyts E, Main KM. 2001. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 16:972–978.


REFERENCES


Barlow NJ, McIntyre BS, Foster PM. 2004. Male reproductive tract lesions at 6, 12, and 18 months of age following in utero exposure to di-(n-butyl) phthalate. Toxicol Pathol 32:78–95.


